Recently, an increased risk of death associated with the use of ACE inhibitors and ARBs in COVID-19 patients was not found [36], but the risk in patients having sarcoidosis too, due to the co-existing polymorphisms affecting the ACE2 system might be increased [30]. Here, ACE is linked to COVID-19.